Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus

Pediatric Diabetes

Volumn 17, Issue 6, 2016, Pages 426-432

  Banser, Alena ^a   Naafs, Jolanda C ^b   Hoorweg Nijman, Jantine J G ^b   van de Garde, Ewoudt M W ^a,b   van der Vorst, Marja M J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

AGEs; children; HbA1c; sAF; type 1 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ARTICLE; AUTOFLUORESCENCE; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHOOL CHILD; SKIN AUTOFLUORESCENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84982952348     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12311     Document Type: Article

References (33)

1. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978: 200: 21–27.
2. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995: 18: 440–447.
3. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008: 93: 1143–1152.
4. Verzijl N, DeGroot J, Thorpe SR et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000: 275: 39027–39031.
5. Lutgers HL, Graaff R, Links TP et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006: 29: 2654–2659.
6. Monnier VM, Bautista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999: 48: 870–880.
7. Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005: 54: 3103–3111.
8. Felipe DL, Hempe JM, Liu S et al. Skin intrinsic fluorescence is associated with hemoglobin A(1c) and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes. Diabetes Care 2011: 34: 1816–1820.
9. Koetsier M, Nur E, Chunmao H et al. Skin color independent assessment of aging using skin autofluorescence. Opt Express 2010: 18: 14416–14429.
10. Meerwaldt R, Graaff R, Oomen PH et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004: 47: 1324–1330.
11. Genevieve M, Vivot A, Gonzalez C et al. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Diabetes Metab 2013: 39: 349–354.
12. Sugisawa E, Miura J, Iwamoto Y, Uchigata Y. Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care 2013: 36: 2339–2345.
13. Barat P, Cammas B, Lacoste A et al. Advanced glycation end products in children with type 1 diabetes: family matters? Diabetes Care 2012: 35: e1.
14. Baez EA, Shah S, Felipe D, Maynard J, Lefevre S, Chalew SA. Skin advanced glycation endproducts are elevated at onset of type 1 diabetes in youth. J Pediatr Endocrinol Metab 2015: 28: 133–137.
15. Shah S, Baez EA, Felipe DL, Maynard JD, Hempe JM, Chalew SA. Advanced glycation endproducts in children with diabetes. J Pediatr 2013: 163: 1427–1431.
16. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol Ther 2010: 12: 399–403.
17. Mulder DJ, Water TV, Lutgers HL et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006: 8: 523–535.
18. Smit AJ, Smit JM, Botterblom GJ, Mulder DJ. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLoS One 2013: 8: e65592.
19. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988: 124: 869–871.
20. den Engelsen C, van den Donk M, Gorter KJ, Salome PL, Rutten GE. Advanced glycation end products measured by skin autofluorescence in a population with central obesity. Dermatoendocrinol 2012: 4: 33–38.
21. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000: 28: 1708–1716.
22. Cerami A. The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's. J Intern Med 2012: 271: 219–226.
23. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003: 26: 2609–2615.
24. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002: 251: 87–101.
25. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Skin autofluorescence and glycemic variability. Diabetes Technol Ther 2010: 12: 581–585.
26. Stirban A, Nandrean S, Negrean M, Koschinsky T, Tschoepe D. Skin autofluorescence increases postprandially in human subjects. Diabetes Technol Ther 2008: 10: 200–205.
27. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008: 7: 29.
28. Samuelsson U, Steineck I, Gubbjornsdottir S. A high mean-HbA1c value 3–15 months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood--a pilot study using two nation-wide population based quality registries. Pediatr Diabetes 2014: 15: 229–235.
29. Araszkiewicz A, Naskret D, Niedzwiecki P, Samborski P, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes. Diabetes Technol Ther 2011: 13: 837–842.
30. Januszewski AS, Sachithanandan N, Karschimkus C et al. Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med 2012: 29: 726–733.
31. Orchard TJ, Lyons TJ, Cleary PA et al. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care 2013: 36: 3146–3153.
32. Chabroux S, Canoui-Poitrine F, Reffet S et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 2010: 36: 152–157.
33. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014: 2: CD009122.